Literature DB >> 16212240

Mutant presenilin 2 increases acetylcholinesterase activity in neuronal cells.

Hong Nga Nguyen1, Dae Youn Hwang, Young Kyu Kim, Do Young Yoon, Jae Hwa Kim, Moon Soon Lee, Myung Koo Lee, Yeo Pyo Yun, Ki Wan Oh, Jin Tae Hong.   

Abstract

A presenilin 2 mutation is believed to be involved in the development of Alzheimer's disease. In addition, transgenic mice with a presenilin 2 mutation have been reported to have learning and memory impairments. In this study, exposing PC12 cells expressing mutant presenilin 2 to 50 microM AP25-35, 30 mM L-glutamate and 50 microM H2O2 caused a significant increase in acetylcholine esterase activity. An in vivo study revealed high levels of this enzyme activity in the mutant presenilin 2 transgenic brains compared with the wild type presenilin 2 transgenic and nontransgenic samples. These results suggest that a mutant presenilin 2-induced neurodegeneration in Alzheimer's disease might be involved in the increase in acetylcholinesterase activity. These findings might help in the development of an appropriate therapeutic intervention targeting mutant presenilin 2-induced Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16212240     DOI: 10.1007/bf02977404

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  3 in total

1.  Presenilin 1 interacts with acetylcholinesterase and alters its enzymatic activity and glycosylation.

Authors:  María-Ximena Silveyra; Geneviève Evin; María-Fernanda Montenegro; Cecilio J Vidal; Salvador Martínez; Janetta G Culvenor; Javier Sáez-Valero
Journal:  Mol Cell Biol       Date:  2008-02-25       Impact factor: 4.272

2.  Presenilin 2 overexpression is associated with apoptosis in Neuro2a cells.

Authors:  Ashish Kumar; T M Sivanandam; M K Thakur
Journal:  Transl Neurosci       Date:  2016-08-01       Impact factor: 1.757

3.  N-acetylcholinesterase-induced apoptosis in Alzheimer's disease.

Authors:  Debra Toiber; Amit Berson; David Greenberg; Naomi Melamed-Book; Sophia Diamant; Hermona Soreq
Journal:  PLoS One       Date:  2008-09-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.